Drug Database
Back to search

Czechia· CZ-0210050

GAZYVARO

A obinutuzumab product containing obinutuzumab, registered in Czechia by Roche Registration GmbH, Grenzach-Wyhlen. The same ATC class is registered in 12 of our 19 countries.

ATC L01FA03

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedGAZYVAROATCL01FA03REGISTER NO.CZ-0210050PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about obinutuzumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Obinutuzumab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FA03 (obinutuzumab), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 7 of them publish a price we can compare per daily dose
Search obinutuzumab products by name

Obinutuzumab · ATC L01FA03

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of obinutuzumab costs, country by country.

Normalised to the WHO defined daily dose (35.7 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Obinutuzumab · price per daily dose (35.7 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$143.26
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

SÚKL (Czech Republic)
Active substance
OBINUTUZUMAB
Manufacturer
Roche Registration GmbH, Grenzach-Wyhlen
Country
Czechia (CZ)
ATC code
L01FA03
ATC class
Obinutuzumab
Defined daily dose
35.7 mg, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0210050
    1X40ML
    CZK 87479.57

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

72 interactions on record for obinutuzumab.

Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check obinutuzumab against other medicinesHow interaction checks work

Obinutuzumab · interactions on record

72 records

  • 29 severe
  • 43 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Obinutuzumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All obinutuzumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Gazyvaro
  • Liechtenstein · Gazyvaro
  • Norway · Gazyvaro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8691b13c-becc-45b2-b6ac-3362ac34d754
GET /v1/drugs/8691b13c-becc-45b2-b6ac-3362ac34d754?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INF CNC SOL",
  "source": "sukl",
  "strength": "1000MG",
  "pack_size": "1X40ML",
  "substance": "OBINUTUZUMAB",
  "cz_kod_sukl": "0210050",
  "product_type": "BT",
  "substance_codes": "18253",
  "registration_state": "R",
  "registration_number": "EU/1/14/937/001"
}
API referenceMCP serverPlans

See everything about obinutuzumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console